EIF2AK4 and COVID-19: Furthermore, we revealed that two GCN2 pharmacologic inhibitors, GCN2iB and GCN2-IN-1, could significantly reduce ACE2 protein expression in CCD841 cells, making them candidate drugs for ameliorating the gastrointestinal symptoms in patients with COVID-19.